Read articles from United States of America

October 09, 2026 by regulatorwatch.com

A reset of the FDA’s PMTA process is overdue if regulation is meant to guide the market rather than paralyse it. The current pathway has left many smoke-free products trapped in uncertainty while cigarettes remain legally available and illicit alternatives gain space. A better system should be rigorous, transparent and fast enough to distinguish responsible products from those that do not meet standards. Harm reduction depends on regulation that can make timely decisions, not one that delays safer options out of reach.

October 09, 2026 by pearlsandirritations.com

Australia’s nicotine policy is drifting further from the reality consumers are living in. Cigarettes remain legal, illicit tobacco is expanding, and many vapers are navigating workarounds, informal supply or rules that do not match how people actually quit smoking. That gap matters because policy cannot reduce harm effectively while pretending demand has disappeared or that restriction equals control. A better approach would start from real behaviour: keep people inside legal channels, make safer alternatives accessible, and measure success by fewer people smoking.

October 08, 2026 by 2firsts.com

The FDA’s tobacco centre reworking its product review process matters because the current system has struggled to keep pace with the market it is supposed to regulate. Slow, uncertain pathways can leave responsible products waiting while cigarettes remain widely available and unapproved alternatives continue to circulate. A better review model should be faster without becoming weaker: clear standards, transparent decisions and evidence assessed according to relative risk. The goal should be a legal market where safer nicotine products are reviewed in time to help smokers move away from combustion.

October 08, 2026 by 2firsts.com

The FDA’s tobacco centre reworking its product review process matters because the current system has struggled to keep pace with the market it is supposed to regulate. Slow, uncertain pathways can leave responsible products waiting while cigarettes remain widely available and unapproved alternatives continue to circulate. A better review model should be faster without becoming weaker: clear standards, transparent decisions and evidence assessed according to relative risk. The goal should be a legal market where safer nicotine products are reviewed in time to help smokers move away from combustion.

October 06, 2026 by gfn.tv

Better regulation begins with a simple discipline: look at the evidence before deciding what the policy should say. In tobacco and nicotine control, that means distinguishing between products, measuring actual exposure, and asking whether rules help smokers move away from combustion. Regulation that ignores evidence may still look decisive, but it can harden the wrong incentives and leave the greatest harms untouched. The challenge is not more regulation for its own sake — it is regulation that is proportionate, responsive and honest about risk.

October 06, 2026 by protectingtaxpayers.org

The Fifth Circuit ruled that the FDA unlawfully imposed a comparative efficacy standard on flavored vaping products without the notice-and-comment process required by the Administrative Procedure Act. The standard required manufacturers to demonstrate greater benefits for adult smokers than tobacco-flavored products, contributing to widespread marketing denials. The text argues that these barriers restrict potentially lower-risk alternatives for smokers and increase healthcare costs. It also distinguishes lack of FDA authorization from proof that a product is dangerous, noting that authorization does not establish safety. The ruling calls for lawful, transparent regulation that protects young people, allows businesses fair participation, and preserves adult access to potentially beneficial alternatives to cigarettes.

October 05, 2026 by substack.com

The author argues that tobacco harm reduction (THR) should extend beyond helping current smokers switch to lower-risk nicotine products. US data show stable overall nicotine use alongside declining smoking and rising vaping, particularly among young adults. The author interprets these trends as suggesting that vaping may divert some people from smoking, although population trends alone cannot establish causation. THR could therefore include switching, maintaining smoking abstinence, and preventing smoking among would-be smokers. Whether vaping benefits never-smokers depends on whether they would otherwise smoke or remain nicotine-free. The author recommends broader messaging, research, and population models examining these counterfactuals to sustain THR’s relevance as cigarette smoking declines.

October 02, 2026 by reason.com

Easthampton became Massachusetts’ 25th municipality to adopt a lifetime nicotine-sales ban for younger generations, including noncombustible products. The author argues these policies conflate nicotine with smoking’s combustion-related harms and undermine harm reduction. Nicotine is addictive and carries cardiovascular and adolescent risks, but research suggests potential cognitive benefits, though therapeutic evidence remains preliminary. Comparing nicotine with caffeine and accepted nicotine-replacement therapies, the text criticizes restrictions on adult choice and the goal of eliminating nicotine use rather than smoking-related disease. It also warns that prohibition could encourage poorly studied, potentially stronger synthetic alternatives. The author advocates distinguishing nicotine from cigarettes and weighing its risks and benefits rather than treating it as inherently unacceptable.

October 02, 2026 by cspdailynews.com

The article portrays FDA tobacco director Bret Koplow as shifting regulation toward harm reduction after years of approval backlogs and limited support for cigarette alternatives. Speaking at a tobacco retailers’ conference, Koplow advocated cooperation with manufacturers and retailers to protect minors, accelerate authorization of scientifically supported lower-risk products for adults, and combat illicit e-cigarettes. His authorization of vaping and nicotine pouch products has drawn praise from industry and opposition from public health groups. Koplow emphasizes that no tobacco product is safe and quitting is healthiest, but completely switching from cigarettes to FDA-authorized, noncombustible alternatives can reduce exposure to toxic and cancer-causing chemicals.

October 02, 2026 by protectingtaxpayers.org

The text argues that growing evidence supports tobacco harm reduction products, especially e-cigarettes, as alternatives for adult smokers. It cites a Cochrane review of nine trials finding vaping more effective than traditional nicotine replacement therapies for quitting, with no serious harms identified in those trials. It also describes FDA authorization of reduced-risk marketing claims for ZYN nicotine pouches. The author contends that restrictive policies discourage cessation and fuel illicit markets, while cigarette smoking causes substantial mortality and economic costs. The text urges clinicians and policymakers to prioritize scientific evidence over stigma and prohibition, arguing that access to lower-risk nicotine products could improve public health.